Medpace Holdings (MEDP) Stock Forecast & Price Target

Compare

645 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MEDP Analyst Ratings

Hold

1 Buy

5 Hold

2 Sell

Based on 8 analysts giving stock ratings to

Medpace

Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MEDP Stock 12 Month Forecast

Average Price Target

$557.50

▼(-1.91% Downside)

Based on 8 Wall Street analysts offering 12 month price targets for Medpace Holdings in the last 3 months. The average price target is $557.50 with a high forecast of $655.00 and a low forecast of $462.00. The average price target represents a -1.91% change from the last price of $568.36.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"296":"$296","386":"$386","476":"$476","566":"$566","656":"$656"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":655,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$655.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":557.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$557.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":462,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$462.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[296,386,476,566,656],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,587.98,593.1353846153846,598.2907692307692,603.4461538461538,608.6015384615384,613.756923076923,618.9123076923076,624.0676923076924,629.223076923077,634.3784615384616,639.5338461538462,644.6892307692308,649.8446153846154,{"y":655,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,587.98,585.6353846153846,583.2907692307692,580.9461538461538,578.6015384615384,576.256923076923,573.9123076923076,571.5676923076924,569.223076923077,566.8784615384616,564.5338461538462,562.1892307692308,559.8446153846154,{"y":557.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,587.98,578.2892307692308,568.5984615384616,558.9076923076923,549.2169230769231,539.5261538461539,529.8353846153847,520.1446153846153,510.45384615384614,500.76307692307694,491.0723076923077,481.38153846153847,471.6907692307692,{"y":462,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":342.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":349.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.73,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":321.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":423.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":473.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":543.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":584.91,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":587.98,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$655.00

Average Price Target$557.50

Lowest Price Target$462.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Luke Sergott

Barclays

$425→$525

Sell

-7.63%

Downside

Reiterated

12/15/25

Medpace Holdings (MEDP) Gets a Sell from Barclays

Jailendra Singh

Truist Financial

―

Hold

―

Reiterated

12/09/25

Analysts Offer Insights on Healthcare Companies: Medpace Holdings (NASDAQ: MEDP) and Nurix Therapeutics (NASDAQ: NRIX)

Sean Dodge

BMO Capital

$600

Hold

5.57%

Upside

Initiated

11/12/25

Medpace initiated with a Market Perform at BMO CapitalMedpace initiated with a Market Perform at BMO Capital

Ann Hynes

Mizuho Securities

$575→$655

Buy

15.24%

Upside

Reiterated

10/24/25

Medpace price target raised to $655 from $575 at MizuhoMedpace price target raised to $655 from $575 at Mizuho

Eric Coldwell

Robert W. Baird

$491→$613

Hold

7.85%

Upside

Reiterated

10/24/25

Medpace price target raised to $613 from $491 at BairdMedpace price target raised to $613 from $491 at Baird

Charles Rhyee

TD Cowen

$356→$462

Sell

-18.71%

Downside

Reiterated

10/24/25

Medpace Holdings: Overvaluation Concerns Amid Growth Projections and Market Positioning

Max Smock

William Blair

―

Hold

―

Reiterated

10/23/25

Medpace Holdings: Strong Q3 Performance Amid Valuation and Growth Sustainability Concerns

Michael Cherny

Leerink Partners

$455→$490

Hold

-13.79%

Downside

Reiterated

10/08/25

Leerink Partners Keeps Their Hold Rating on Medpace Holdings (MEDP)

David Windley

Jefferies

$400→$450

Hold

-20.82%

Downside

Reiterated

09/08/25

Jefferies Reaffirms Their Hold Rating on Medpace Holdings (MEDP)

Jamie Clark

Rothschild & Co Redburn

$342→$474

Hold

-16.60%

Downside

Downgraded

09/03/25

Redburn Atlantic downgrades Medpace Holdings (MEDP) to a HoldRothschild Redburn analyst Jamie Clark downgraded Medpace (NASDAQ: MEDP) from Buy to Neutral with a price target of $474.00 (from $342.00).

Dan Leonard

UBS

$300→$305

Sell

-46.34%

Downside

Downgraded

07/29/25

Medpace downgraded to Sell from Neutral at UBSMedpace downgraded to Sell from Neutral at UBS

Justin Bowers

Deutsche Bank

$270→$430

Hold

-24.34%

Downside

Reiterated

07/23/25

Medpace price target raised to $430 from $270 at Deutsche BankMedpace price target raised to $430 from $270 at Deutsche Bank

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Luke Sergott

Barclays

$425→$525

Sell

-7.63%

Downside

Reiterated

12/15/25

Medpace Holdings (MEDP) Gets a Sell from Barclays

Jailendra Singh

Truist Financial

―

Hold

―

Reiterated

12/09/25

Analysts Offer Insights on Healthcare Companies: Medpace Holdings (NASDAQ: MEDP) and Nurix Therapeutics (NASDAQ: NRIX)

Sean Dodge

BMO Capital

$600

Hold

5.57%

Upside

Initiated

11/12/25

Medpace initiated with a Market Perform at BMO CapitalMedpace initiated with a Market Perform at BMO Capital

Ann Hynes

Mizuho Securities

$575→$655

Buy

15.24%

Upside

Reiterated

10/24/25

Medpace price target raised to $655 from $575 at MizuhoMedpace price target raised to $655 from $575 at Mizuho

Eric Coldwell

Robert W. Baird

$491→$613

Hold

7.85%

Upside

Reiterated

10/24/25

Medpace price target raised to $613 from $491 at BairdMedpace price target raised to $613 from $491 at Baird

Charles Rhyee

TD Cowen

$356→$462

Sell

-18.71%

Downside

Reiterated

10/24/25

Medpace Holdings: Overvaluation Concerns Amid Growth Projections and Market Positioning

Max Smock

William Blair

―

Hold

―

Reiterated

10/23/25

Medpace Holdings: Strong Q3 Performance Amid Valuation and Growth Sustainability Concerns

Michael Cherny

Leerink Partners

$455→$490

Hold

-13.79%

Downside

Reiterated

10/08/25

Leerink Partners Keeps Their Hold Rating on Medpace Holdings (MEDP)

David Windley

Jefferies

$400→$450

Hold

-20.82%

Downside

Reiterated

09/08/25

Jefferies Reaffirms Their Hold Rating on Medpace Holdings (MEDP)

Jamie Clark

Rothschild & Co Redburn

$342→$474

Hold

-16.60%

Downside

Downgraded

09/03/25

Dan Leonard

UBS

$300→$305

Sell

-46.34%

Downside

Downgraded

07/29/25

Medpace downgraded to Sell from Neutral at UBSMedpace downgraded to Sell from Neutral at UBS

Justin Bowers

Deutsche Bank

$270→$430

Hold

-24.34%

Downside

Reiterated

07/23/25

Medpace price target raised to $430 from $270 at Deutsche BankMedpace price target raised to $430 from $270 at Deutsche Bank

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medpace Holdings

1 Month

xxx

Success Rate

5/9 ratings generated profit

Average Return

+4.97%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +4.97% per trade.

3 Months

xxx

Success Rate

4/9 ratings generated profit

Average Return

+5.91%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +5.91% per trade.

1 Year

Ann HynesMizuho Securities

Success Rate

6/7 ratings generated profit

Average Return

+34.63%

reiterated a buy rating 2 months ago

Copying Ann Hynes's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +34.63% per trade.

2 Years

xxx

Success Rate

7/7 ratings generated profit

Average Return

+49.20%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +49.20% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MEDP Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MEDP has received 4 Buy Ratings, 8 Hold Ratings, and 4 Sell Ratings. MEDP average Analyst price target in the past 3 months is 557.50.

Each month's total comprises the sum of three months' worth of ratings.

MEDP Financial Forecast

MEDP Earnings Forecast

Next quarter’s earnings estimate for MEDP is $4.18 with a range of $4.09 to $4.35. The previous quarter’s EPS was $3.86. MEDP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MEDP has Performed in-line its overall industry.

MEDP Sales Forecast

Next quarter’s sales forecast for MEDP is $689.39M with a range of $678.50M to $708.49M. The previous quarter’s sales results were $659.90M. MEDP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MEDP has Performed in-line its overall industry.

MEDP Stock Forecast FAQ

What is MEDP’s average 12-month price target, according to analysts?

Based on analyst ratings, Medpace Holdings’s 12-month average price target is 557.50.

What is MEDP’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for MEDP, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MEDP a Buy, Sell or Hold?

Medpace Holdings has a consensus rating of Hold which is based on 1 buy ratings, 5 hold ratings and 2 sell ratings.

What is Medpace Holdings’s price target?

The average price target for Medpace Holdings is 557.50. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $655.00 ,the lowest forecast is $462.00. The average price target represents -1.91% Decrease from the current price of $568.36.

What do analysts say about Medpace Holdings?

Medpace Holdings’s analyst rating consensus is a Hold. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of MEDP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Medpace Holdings (MEDP) Stock Forecast & Price Target

MEDP Analyst Ratings

MEDP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Medpace Holdings

MEDP Analyst Recommendation Trends

MEDP Financial Forecast

MEDP Earnings Forecast

MEDP Sales Forecast

MEDP Stock Forecast FAQ

Detailed List of Analyst Forecasts